This study is for people with certain types of cancer called NSCLC (Non-Small Cell Lung Cancer) and other solid tumors. These cancers have changes in a gene called ALK, which makes them grow. The study tests a new medicine called NVL-655 to see if it is safe and works well.

The study has two parts, called phases. **Phase 1** checks for safety and the right dose. **Phase 2** looks at how well the medicine helps patients. The study divides patients into groups based on their past treatments and how advanced their cancer is.

People can join if they are over 18 years old (or 12 years for some cases), have a tumor with ALK changes, and meet other health requirements. They cannot join if they have other cancer-driving genes, allergies to the medicine, or have had major surgery recently.

• The study involves both receiving the new medicine and regular check-ups.
• There might be side effects, but the study will help find the safest dose.
• People in the study may help discover a new treatment for their cancer type.